Drug Controller General India: The DCGI has approved emergency use of anti covid drug labelled ‘2-deoxy-D-glucose (2-DG)’ as an adjunct therapy for use in moderate to severe cases.
“Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty,” said the DCGI in a statement.
DCGI has granted permission for emergency use of therapeutic application of drug 2-deoxy-D-glucose (2-DG) as adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule & analogue of glucose, it can be easily produced & made available in plenty: DRDO pic.twitter.com/2TJA4S1cAV
— ANI (@ANI) May 8, 2021
The drug has been developed to combat the multiplication of COVID-19 cells in the body, and clinical trials have shown promise in the moderate to severe cases in specific focus groups.
DCGI approves anti-COVID drug developed by DRDO for emergency use. Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.#IndiaFightsCorona pic.twitter.com/s90x1rNhhF
— All India Radio News (@airnewsalerts) May 8, 2021
“A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SOC,” said the DCGI.
A major Covid-19 treatment breakthrough has been announced just now by the Defence R&D Organisation @DRDO_India.
Phase-III clinical trial conducted on 220 patients between Dec 2020 to March 2021 at 27 COVID hospitals.
Drugs Controller General of India (DCGI) has given its okay.
— Ajai Shukla (@ajaishukla) May 8, 2021
Impact on the Indian second wave: As India battles the menace of the second wave, 1.5 million cases have been recorded in the past week nationwide. The uncontrollable spread of the virus has reached the rural areas, and experts said the third wave will be imminent if this is not contained. An oral anti COVID drug combined with the COVID-19 vaccination efforts could provide the toolbox for an effective framework to battle the spread of the virus in the country.
DCGI Approves Anti-COVIDDrug Developed by DRDO for Emergency use#UserGeneratedContent | @manjeetnegilive
(@DRDO_India) pic.twitter.com/zlq2jBXFlb— IndiaToday (@IndiaToday) May 8, 2021